title: [ADVANCE-ON Trial: How to Achieve Maximum Reduction of Mortality in Patients With Type 2 Diabetes].
abstract: Of 10 261 patients with type 2 diabetes who survived to the end of a randomized ADVANCE trial 83% were included in the ADVANCE-ON project for observation for 6 years. The difference in the level of blood pressure which had been achieved during 4.5 years of within trial treatment with fixed perindopril/indapamide combination quickly vanished but significant decrease of total and cardiovascular mortality in the group of patients treated with this combination for 4.5 years was sustained during 6 years of post-trial follow-up. The results can be related to gradually weakening protective effect of perindopril/indapamide combination on cardiovascular system, and are indicative of the expedience of long-term use of this antihypertensive therapy for maximal lowering of mortality of patients with diabetes.
authors.affiliation: Kuban State Medical University, Sedina St., 4, 350063 Krasnodar, Russia.
authors.forename: S G
authors.initials: SG
authors.lastname: Kanorsky